.png)
.jpg)
Mission + Process
Digitalis Commons develops biomedical technologies that are frontier-advancing, open-access, and scalable in areas where market incentives are insufficient to serve the public interest.
Much of modern biomedical technology is shaped by commercial logic—venture capital, intellectual property protection, and return on investment. This system produces important innovations, but it also leaves critical gaps: diseases that are neglected, foundational tools that become enclosed, and publicly funded discoveries that fail to translate into broadly accessible solutions. Digitalis Commons exists to work in those gaps.
We develop technologies guided not only by what is possible or profitable, but by a more fundamental question: who benefits, and how broadly?
Digitalis Commons is part of the Digitalis Group which also includes Digitalis Research, an applied research organization building new ideas at the intersection of health and technology, and Digitalis Ventures, a venture capital firm investing in solutions to unmet needs in health. Digitalis Commons partners with Digitalis Research to identify structural problems ripe for change, identify potential solutions, and test them in real-world practice.
Public Interest
Biomedical Technologies
We focus on a distinct category of work: public interest biomedical technologies—innovations that are scientifically viable and societally valuable, but structurally underserved by traditional market dynamics.
These include:
- Technologies targeting diseases or conditions that are neglected because affected populations cannot support commercial returns
- Platforms, tools, or discoveries that are too foundational to be optimally developed as proprietary assets
- Technologies emerging from significant public funding where broad access is a legitimate expectation
- Approaches to medicine that treat access and affordability as design constraints, not afterthoughts
Development Model
Digitalis Commons operates as a technology developer. We take responsibility for advancing technologies through the translational pipeline—from early scientific work through regulatory strategy, manufacturing partnerships, and clinical evidence generation.
Where full in-house development is impractical, we act as a lead steward, coordinating consortia of academic, nonprofit, and industry partners while maintaining control over the conditions that define the public interest mission.
Our model is built around three core commitments:
- Rigorous technology selection
- Access-preserving intellectual property practices
- Financing structures that protect mission integrity
1. Technology Selection
We pursue opportunities at the intersection of:
- High unmet need
- Demonstrated market failure
- Development tractability
This framing is deliberate. Many important problems are either scientifically intractable or already well-served by commercial incentives. Our focus is on the narrower set of opportunities where meaningful progress is both possible and unlikely to occur without intervention.
Opportunities emerge from a combination of scientific research, domain expertise, and investment intelligence developed across the Digitalis ecosystem. This allows us to identify technologies that are not only neglected, but actionable.
Our selection process asks a critical additional question:
Would Commons-style development produce a meaningfully different outcome than leaving this opportunity to the market?
2. Intellectual Property
Our intellectual property approach is designed to ensure that access is preserved as a non-negotiable condition, not something retrofitted after commercialization.We treat IP as a tool for shaping outcomes—not simply for exclusion or value capture.
Core principles include:
Defensive publication as a default starting point
Where appropriate, we publish findings to establish prior art and prevent enclosure of foundational technologies.
Access-conditioned licensing
When patents are held, licensing terms are structured in advance to include access provisions—such as tiered pricing, field-of-use constraints, or sublicensing rights that preserve downstream innovation.
Geographic differentiation
Commercial rights may be licensed in high-income markets while access is retained or separately structured in lower-income settings, using revenues from the former to support the latter.
Open licensing for platform technologies
For enabling tools and infrastructure, open models may be used to maximize downstream development and impact.
Retention of march-in or intervention rights
Where third parties are involved, we maintain the ability to intervene if pricing or availability diverges from the public interest mission.
3. Financing
Digitalis Commons is a mission-driven 501(c)(3) organization. It is not structured to maximize financial return—but it is also not purely philanthropic. Instead, it operates with a hybrid financing model designed to sustain long-term development without compromising mission.
This model includes:
- Philanthropic capital
- Public and government funding
- Earned income
- Revenue from access-conditioned licensing arrangements
The objective is to build an organization that becomes progressively more self-sustaining, while remaining anchored to public interest goals.
Where viable markets exist, we use them. Where they do not, we build alternative support structures. In both cases, financing is designed to enable access, not constrain it.
ABOUT OUR NAME
The Digitalis plant is the natural source of cardioactive steroid glycosides widely used in the treatment of heart disease since the 1700s. Dr. Thomas W. Smith, the father of our founding partner, began his career as a physician-scientist at Harvard by developing a novel radioimmunoassay to enable the safe administration of digitalis. Dr. Smith’s subsequent research program touched on many themes—the health benefits of nature-derived compounds, the importance of measurement science in therapeutic development, rational design in drug discovery, among many others that continue to resonate with our group today. Beyond his research, Dr. Smith was a renowned clinician and beloved mentor to a generation of academic cardiologists. Our name reflects our ongoing commitment to this legacy of both scientific innovation and human connection.
.svg)